Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought

Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought

Upworthy

Published

Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but…

#pfizer #moderna #newyorkcity #pfizerinc #jpmorgan

Full Article